Hypermarcas (OTCMKTS:HYPMY) Short Interest Up 183.8% in July

Hypermarcas (OTCMKTS:HYPMY) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 5,807 shares, a growth of 183.8% from the June 30th total of 2,046 shares. Based on an average daily volume of 27,320 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are sold short.

Hypermarcas Price Performance

Hypermarcas stock opened at $3.98 on Monday. Hypermarcas has a 12-month low of $3.71 and a 12-month high of $5.50. The stock has a market capitalization of $2.80 billion, a P/E ratio of 8.29 and a beta of 0.71. The firm’s 50-day moving average is $4.15 and its two-hundred day moving average is $4.38.

Hypermarcas (OTCMKTS:HYPMY) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $0.10 earnings per share for the quarter. The business had revenue of $383.13 million during the quarter. Hypermarcas had a net margin of 19.41% and a return on equity of 14.08%. As a group, analysts forecast that Hypermarcas will post 0.53 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Jefferies Financial Group upgraded Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. Zacks Research raised Hypermarcas to a “hold” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Hypermarcas has an average rating of “Buy”.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.